Tests a GLP-1 drug with metformin before fertility treatment in women with PCOS
Tests a GLP-1 drug with metformin in women with PCOS and obesity before fertility care.
Plain-language title generated from the registry record
Registry title: Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 40 who have PCOS and obesity and want to become pregnant. It tests a GLP-1 drug with metformin and lifestyle education before fertility treatment.
- Age
- 18 Years to 40 Years
- Sex
- Women only
- Disease stage
- PCOS (Rotterdam criteria) with BMI from 28 kg/m2 up to less than 35 kg/m2.
- Earlier treatment
- Cannot have used glucocorticoids or anti-androgen drugs (such as spironolactone, cyproterone acetate, flutamide) in the last 3 months. Cannot be on weight loss therapy (more than 5% weight loss in the last 3 months) or have had gastrointestinal surgery.
Main reasons for not taking part
- Other medical illness or endocrine disorders
- Abnormal liver or kidney function
- Acute infection, severe heart disease or cancer
- Uterine abnormalities or untreated tubal hydrosalpinx
- Allergy to or contraindication for GLP-1 class medicines
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06775093, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaContact: Shuo HuangNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT06775093
- Record updated
- 14 January 2025
- Original description
The goal of this clinical trial is to examine whether benalutide combined with metformin and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.Read full original descriptionShow less
Effects of GLP-1 Receptor Agonists Combined with Metformin and Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Women with PCOS and Obesity
The goal of this clinical trial is to examine whether benalutide combined with metformin and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.
Inclusion: Women with a wish to conceive; Women with PCOS (Rotterdam criteria); 28 kg/m2≤BMI<35kg/m2.
Exclusion: Women with medical morbidity; Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine anomalies or untreated tubal hydrosalpinx; Receiving a donor oocyte or donor sperm cycle; Chromosome abnormality or recurrent miscarriage; planning preimplantation genetic testing (PGT); Any other contraindications to fertility treatment; Allergic to or contraindicated for GLP-1 class medications.